Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome

Autor: Ruiz-Pinto, S., Pita, G., Patiño-García, A., García-Miguel, P., Alonso, J., Pérez-Martínez, A., Sastre, A., Gómez-Mariano, G., Lissat, A., Scotlandi, K., Serra, M., Ladenstein, R., Lapouble, E., Pierron, G., Kontny, U., Picci, P., Kovar, H., Delattre, O., González-Neira, A. ^*

Publikováno v: In Annals of Oncology September 2016 27(9):1788-1793

Automated compound testing in zebrafish xenografts identifies combined MCL-1 and BCL-XL inhibition to be effective against Ewing sarcoma

Autor: Wenninger-Weinzierl A, Martin Distel, Didier Surdez, Kovar H, Pascoal S, Bierbaumer L, Scheuringer E, Toetzl M, Caterina Sturtzel, Sarah Grissenberger, Tomazou E, Halbritter F, Olivier Delattre

Ewing sarcoma is a pediatric bone and soft tissue cancer for which new therapies to improve disease outcome and to reduce adverse effects of current standard treatments are urgently needed. To identify new and effective drugs, phenotypic drug screeni

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0058d8d9f0cc997b370c11c0e4a1e837
https://doi.org/10.1101/2021.06.17.448794

An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma.

Autor: Shulman DS; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA., Whittle SB; Texas Children's Cancer and Hematology Centers, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA., Surdez D; Bone Sarcoma Research Laboratory, Balgrist University Hospital, University of Zurich, Zurich, Switzerland., Bailey KM; Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., de Álava E; Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital/CSIC/University of Sevilla/CIBERONC/Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, Seville, Spain., Yustein JT; Texas Children's Cancer and Hematology Center and The Faris D. Virani Ewing Sarcoma Center, Baylor College of Medicine, Houston, TX, USA., Shlien A; Department of Laboratory Medicine and Pathobiology/Department of Paediatric Laboratory Medicine/Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada., Hayashi M; Department of Pediatrics, University of Colorado Anschutz Medical Campus and Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO, USA., Bishop AJR; Greehey Children's Cancer Research Institute and Department of Cell Systems and Anatomy, University of Texas Health at San Antonio, San Antonio, TX, USA., Crompton BD; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA., DuBois SG; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA., Shukla N; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Leavey PJ; Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX, USA., Lessnick SL; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, and the Division of Pediatric Heme/Onc/BMT, The Ohio State University College of Medicine, Columbus, OH, USA., Kovar H; St. Anna Children´s Cancer Research Institute (CCRI) and Department Pediatrics Medical University of Vienna, Vienna, Austria., Delattre O; INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, SIREDO Oncology Center, Institut Curie Research Center, Paris, France., Grünewald TGP; Hopp-Children's Cancer Center (KiTZ), Heidelberg/Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK)/Institut of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Antonescu CR; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Roberts RD; Center for Childhood Cancer and Blood Disease, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, USA., Toretsky JA; Departments of Oncology and Pediatrics, Georgetown University, Washington, DC, USA., Tirode F; Univ Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Cancer Research Center of Lyon, Centre Leon Berard, F-69008, Lyon, France., Gorlick R; Division of Pediatrics, MD Anderson Cancer Center, Houston, TX, USA., Janeway KA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA., Reed D; Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, FL, USA., Lawlor ER; Seattle Children's Research Institute, University of Washington Medical School, Seattle, WA, USA., Grohar PJ; Center for Childhood Cancer Research, Children's Hospital of Philadelphia, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. GROHARP@EMAIL.CHOP.EDU.

Publikováno v: NPJ precision oncology [NPJ Precis Oncol] 2022 Sep 17; Vol. 6 (1), pp. 65. Date of Electronic Publication: 2022 Sep 17.

Zooming in on Long Non-Coding RNAs in Ewing Sarcoma Pathogenesis.

Autor: Aryee DNT; St. Anna Children's Cancer Research Institute, 1090 Vienna, Austria.; Department of Pediatrics, Medical University of Vienna, 1090 Vienna, Austria., Fock V; St. Anna Children's Cancer Research Institute, 1090 Vienna, Austria., Kapoor U; St. Anna Children's Cancer Research Institute, 1090 Vienna, Austria., Radic-Sarikas B; St. Anna Children's Cancer Research Institute, 1090 Vienna, Austria.; Department of Pediatric Surgery, Medical University of Vienna, 1090 Vienna, Austria., Kovar H; St. Anna Children's Cancer Research Institute, 1090 Vienna, Austria.; Department of Pediatrics, Medical University of Vienna, 1090 Vienna, Austria.

Publikováno v: Cells [Cells] 2022 Apr 08; Vol. 11 (8). Date of Electronic Publication: 2022 Apr 08.

Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.

Autor: Gagnebin, J, Kovar, H, Kajava, A V, Estreicher, A, Jug, G, Monnier, P, Iggo, R

Publikováno v: Oncogene. 2/5/98, Vol. 16 Issue 5, p685. 6p.